Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viridian Therapeutics Inc VRDN

Healthcare Biotechnology
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and... see more

Recent & Breaking News (NDAQ:VRDN)

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire October 2, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 27, 2023

Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors

Business Wire September 25, 2023

Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September

Business Wire September 7, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire August 25, 2023

Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Business Wire August 8, 2023

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire August 4, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire August 3, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire July 18, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire July 17, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire July 14, 2023

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 11, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire July 11, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viridian Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile July 10, 2023

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Business Wire July 10, 2023

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire July 6, 2023

Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society

Business Wire June 13, 2023

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 5, 2023

Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2023

Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections

GlobeNewswire May 8, 2023